Memorial Sloan-Kettering to use Sutro's technology for new bispecific antibodies Pharmaceutical Business Review PBR Staff Writer Published 08 January 2014. US-based biopharmaceutical firm Sutro Biopharma has entered into a collaboration agreement with Memorial Sloan-Kettering Cancer Center to produce bispecific antibodies for the treatment of neuroblastoma. |
